NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

1991.00 -16.00 (-0.80%)

408.4K NSE+BSE Volume

NSE 24 Sep, 2025 3:30 PM (IST)

90,939.8

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

US FDA Observation

Lupin's Pune biotech facility receives Form 483 with four observations from the US FDA See details

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

16 Feb 2021

1991.00

-0.80%

Monthly Update - IPM grapple for normalized growth after COVID

Buy: Lupin Ltd.

Target

Prabhudas Lilladhar

IPM is struggling for growth above 10% even after MoM abating COVID concerns and with MRs, physician activities almost reaching pre-COVID level. We believe key reasons for growth below par are (i) subdued new prescription (Rx) leading to volume de-growth (ii) digital marketing yield going south and (iii) sustained lower demand of acute products. Cardiac and anti-diabetic growth takes a breather in Jan-21 at 8.8% and 5.3% after reporting double digit growth in most months during lockdown. While amongst top therapies Gastro and VMN reported double digit growth of 14%...

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

03 Feb 2021

1991.00

-0.80%

LUPIN LIMITED

Hold: Lupin Ltd.

Recommendation Target

Geojit BNP Paribas

Lupin Limited is a multi-national pharmaceutical company based in Mumbai. The company specializes in branded and generic formulations, API's and advanced drug delivery systems in the area of biotechnology. The...

Lupin Ltd. is trading below its 200 day SMA of 2025.1

Lupin Ltd.

29 Jan 2021

1991.00

-0.80%

Lupin (ADD): In-line Q3; several near-term catalysts

Accumulate: Lupin Ltd.

Target

BOB Capital Markets Ltd.

Lupin's (LPC) EBITDA was boosted by one-time licensing income (Rs 700mn est.).

Lupin Ltd. is trading above its 150 day SMA of 1980.2

Lupin Ltd.

29 Jan 2021

1991.00

-0.80%

Lupin Ltd

Buy: Lupin Ltd.

Recommendation Target

ICICI Securities Limited

Q3FY21 revenues were in-line with I-direct estimates whereas profitability was above expectations due to better gross margins, cost control and a lower tax outgo. As per the management, FY21 US sales would be largely driven by gLevothyroxine, gProAir ramp-up and 15+ new launches. Domestic branded formulations are expected to remain stable. The resolution of warning letter and clearance of official action indicated (OAIs) status on plants could be the near term lever along with progress on margins front. However, like other pharma majors, Lupin has also chalked out a...

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

12 Jan 2021

1991.00

-0.80%

Initiating Coverage:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We initiating coverage on Lupin with BUY rating and a target price of Rs 1,220 (P/E of 26x for FY23E earnings) which implies an upside of 18% from the current levels.

Lupin Ltd. is trading above its 150 day SMA of 1980.2

Lupin Ltd.

06 Nov 2020

1991.00

-0.80%

Q2FY21 Result Update - Albuterol, Glumetza to be catalyst in 2H - BUY

Buy: Lupin Ltd.

Target

Prabhudas Lilladhar

India formulation remained muted with 1% YoY decline. We reduce our earnings estimate by 7% as we revise our EBITDAM lower to 16% (earlier 19%) for FY21E on the back of increased operating expense. 2QFY21 earnings were below our estimate even with most of the regions except India witnessed good growth. The disappointment was primarily at EBITDA level due to increase in operating expense of 34% QoQ, which led EBITDAM of 14% v/s our estimate of 20%. LPC guided for 18.5% EBITDAM for...

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

06 Nov 2020

1991.00

-0.80%

Profitability on an uptrend for three quarters now

Buy: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) delivered in-line 2QFY21 results. The EBITDA margin has been on an uptrend since hitting all-time lows in 3QFY20, led by cost rationalization, better-than-industry growth in Domestic Formulations (DF), and improved traction in the US/API segment. Near- to medium-term performance is expected to strengthen further on account of recently launched niche products and better operating leverage. We lower our EPS estimate by 5% for FY21, factoring in a gradual increase in Albuterol Sulfate offtake. We maintain our FY22 estimate and introduce...

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

06 Nov 2020

1991.00

-0.80%

Lupin Ltd

Hold: Lupin Ltd.

Target

ICICI Securities Limited

Q2FY21 revenues and operational performance were in-line with I-direct estimates while profitability was below expectations due to below expected other income and a higher tax outgo. As per the management, FY21 US sales would be largely driven by gLevothyroxine, gProAir ramp-up and 15+ new launches. Domestic branded formulations are expected to remain stable. Structurally, the resolution of warning letter and clearance of official action indicated (OAIs) status on plants could be the near term lever along with progress on margins front. Like other pharma majors, Lupin has also...